Compare Supplements

INVESTIGATIONAL — no approved consumer dose. In trials, once-daily oral orforglipron was titrated up to 36 mg (some phase-2 cohorts to 45 mg) with gradual dose escalation to limit GI side effects. Not for self-administration; only appropriate within a clinical trial or, if/when approved, under a prescribing clinician.

Any time

Oral tablet (investigational)

Investigational — NO approved dose. Phase-2 trials used once-weekly subcutaneous injection with stepwise escalation up to 4.8-6.0 mg maintenance. There is no approved regimen; do not self-dose an unapproved drug.

Any time

Once-weekly subcutaneous injection (investigational only)

• Not an approved medicine — only appropriate within a clinical trial or, if/when approved, under a clinician
• Expected: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — the GLP-1-class thyroid C-cell concern
• History of pancreatitis (caution, consistent with the GLP-1 class)

• Insulin and sulfonylureas
• Oral medications (general)
• Other GLP-1 receptor agonists

• Not a dietary supplement and not an approved drug — investigational; do not self-source grey-market vials
• Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
• History of pancreatitis

• Oral medications (delayed gastric emptying)
• Insulin / insulin secretagogues (sulfonylureas)
• Other GLP-1 / incretin drugs